4 January 2021 in Clinical and experimental thyroidology
TATatjana V. Andreychenko
ГБГалина Александровна Богданова
Галина Александровна Богданова
УЦУльяна Александровна Цой
+11
Проект федеральных клинических рекомендаций по диагностике и лечению амиодарон-индуцированной дисфункции щитовидной железы
4 November 2019 in Siberian Journal of Clinical and Experimental Medicine
The present literature review is devoted to the analysis of the features of the pathogenesis of atrial fibrillation in patients with arterial hypertension and to the optimal treatment tactics in this cohort of patients. In particular, pathological mechanisms (hemodynamic, structural, and electrophysiological) of the development of atrial fibrillation in arterial hypertension are reviewed. The article highlights the problems of primary and secondary prevention of atrial fibrillation using antihypertensive therapy as well as the aspects of the prevention of thromboembolic complications in patients with atrial fibrillation and arterial hypertension.
7 March 2023 in Rational Pharmacotherapy in Cardiology
Atrial fibrillation (AF) is strongly associated with stroke risk, but an association by itself does not necessarily imply causation. The question remains whether AF is a risk factor for stroke and whether treatment that reduces the severity of AF will also reduce the burden of stroke. On the other hand, it is possible that AF is a risk marker associated with atrial insufficiency, in which structural and electrical atrial remodeling coexist, leading to the clinical manifestations of AF and the risk of stroke simultaneously. Atrial fibrillation and stroke are inextricably linked to the classic Virchow pathophysiology, which explains thromboembolism as blood stasis in a fibrillating left atrium. This concept has been reinforced by the proven efficacy of oral anticoagulants for the prevention of stroke in AF. However, a number of observations showing that the presence of AF is neither necessary nor sufficient for stroke cast doubt on the causal role of AF in vascular brain injury. The growing recognition of the role of atrial cardiomyopathy and the atrial substrate in the development of stroke associated with AF, as well as stroke without AF, has led to a rethinking of the pathogenetic model of cardioembolic stroke. A number of recent studies have shown that AF is a direct cause of stroke. Studies in which cardiac implantable devices have been used to collect data on pre-stroke AF do not appear to show a direct time relationship. The presence of AF is neither necessary nor sufficient for stroke, which casts doubt on the causal role of AF in cerebrovascular injury. Known risk factors for stroke in the presence of AF are also recognized risk factors for ischemic stroke, regardless of the presence of AF. The risk of stroke in patients with AF in the absence of risk factors differs little from that in patients without AF. This work is devoted to an attempt to answer the question whether AF is a marker or a risk factor for ischemic stroke.
11 January 2024 in Siberian Journal of Clinical and Experimental Medicine
In clinical practice, impaired renal function is often combined with cardiovascular diseases, in particular with atrial fibrillation. As you know, the kidneys perform many functions, including excretory, metabolic and endocrine. The cardiorenal axis is regulated in such a way that an imbalance results in both cardiac and renal remodeling. Therefore, the pathophysiological relationships between the kidneys and the heart are of great clinical importance. Considering the need to create the basis for personalized patient-oriented care, documents on the position of a number of associations and societies dedicated to the treatment of patients with atrial fibrillation and chronic kidney disease are currently presented. Treatment of atrial fibrillation includes prophylactic anticoagulation and pharmacological therapy aimed at maintaining sinus rhythm or correcting the frequency of ventricular responses. At the same time, when choosing the optimal dose of oral direct anticoagulant drugs, there are a number of discrepancies in published regulatory documents of various cardiological and nephrological communities. It should be noted that in recent years there has been no significant improvement in the clinical pharmacology of arrhythmias. Existing pharmacological approaches for the correction of arrhythmias in patients with atrial fibrillation and chronic kidney disease are limited by their limited effectiveness and the possibility of developing dangerous effects, including the proarrhythmic effect against ventricular arrhythmias and organ-toxic complications. The use of catheter and surgical ablation is inhibited by the complexity, cost and high relapse rate in patients with chronic kidney disease. It seems that antiarrhythmic drugs are not given enough attention compared to anticoagulant therapy, especially in patients with atrial fibrillation and chronic kidney disease. This review article discusses approaches to the choice of antiarrhythmic therapy in this category of patients.
15 August 2020 in Russian Journal of Cardiology
Опыт применения пропафенона у новорожденных и детей раннего возраста с нарушениями ритма сердца
1 January 2017 in Russian Journal of Cardiology
Представлены современные эпидемиологические данные о распространенности, инцидентности фибрилляцией предсердий (ФП) и сопутствующей сердечной недостаточности (СН). Изложены основные доказательства увеличения риска тромбоэмболических осложнений у данной категории пациентов, представлены данные эффективности и безопасности прямых пероральных антикоагулянтов у пациентов с ФП и наличием СН, что может способствовать принятию решений в отношении оптимальной антикоагулянтной терапии у данной больных.